Abstracts Archive - Page 1082 of 2607 - ACR Meeting Abstracts

Abstract Number: 2129 • 2019 ACR/ARP Annual Meeting
Thyroperoxidase Antibodies in Patients with Positive ANA
ChiChi Lau¹, Scott Legunn ², Alana Nevares ² and Turner Osler ³, ¹UVM Larner College of Medicine, Burlington, VA, ²UVM Larner College of Medicine, Burlington, VT, ³UVM Larner College of Medicine, Colchester, VT
Background/Purpose: Autoimmune thyroid disease, which is defined by the presence of thyroid antibodies, is the most common organ specific autoimmune disorder, affecting 11% of the…
Abstract Number: 2130 • 2019 ACR/ARP Annual Meeting
Enrichment of IL-17-producing CD4+ T Cells in Synovial Fluid from Patients with Arthritis After anti-CTLA-4 and anti-PD-1 Combination Therapy
Sang Kim¹, Jean Tayar ¹, Maria E. Suárez-Almazor ², Huifang Lu ¹, Yang-Zhi Zhao ¹, Zhongshan Liu ³, Emma Rodriguez ¹, Sattva Neelapu ¹, Jennifer Wang ¹, Amishi Shah ¹, Nizar Tannir ³, Don Gibbons ³, Guillermo Garcia-Manero ³, Hussein Tawbi ³, Patrick Hwu ¹, Andrew Futreal ³, Adi Diab ³ and Roza Nurieva ³, ¹MD Anderson Cancer Center, Houston, TX, ²Department of Rheumatology/Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX , USA., Houston, TX, ³MD Anderson Cancer Center, Houston
Background/Purpose: Immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs), including arthritis (arthritis-irAE). Understanding the pathophysiology of arthritis-irAE is critical to treating it…
Abstract Number: 2131 • 2019 ACR/ARP Annual Meeting
Rituximab Safety and Persistence in Patients with Systemic Autoimmune Diseases
Cristóbal Pavez Perales¹, Jorge Juan Fragio Gil ¹, Roxana Gonzalez Mazarío ¹, José Ivorra Cortés ¹, Elena Grau García ¹, Cristina Alcañiz Escandell ¹, Inmaculada Chalmeta Verdejo ¹, Marta de la Rubia Navarro ¹, Luis González Puig ¹, Isabel Martínez Cordellat ¹, Rosa Negueroles Albuixech ¹, José Eloy Oller Rodríguez ², Francisco Miguel Ortiz-Sanjuán ¹, Elvira Vicens Bernabeu ¹, Carmen Nájera Herranz ¹, Inés Cánovas Olmos ¹, Samuel Leal Rodriguez ¹ and José Andrés Román Ivorra ¹, ¹Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ²Rheumatology Department. HUP La Fe, v, Comunidad Valenciana, Spain
Background/Purpose: Rituximab (RTX), an anti-CD20 monoclonal antibody inducing B cell depletion, is used as therapy for diverse systemic autoimmune diseases (SAIDs), but is associated with adverse events…
Abstract Number: 2132 • 2019 ACR/ARP Annual Meeting
Complement Component 3 as Biomarker of Cardiometabolic Risk in Rheumatic Diseases: Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Systemic Lupus Erythematosus
Ivan Arias de la Rosa¹, Alejandro Escudero ², Maria Dolores Lopez-Montilla ³, Maria del Carmen Abalos-Aguilera ³, Alejandro Ibañez-Costa ³, Carlos Perez-Sanchez ⁴, Rocío Segura-Ruiz ⁵, Alejandra Patiño-Trives ³, Maria Luque-Tevar ³, Carmen Torres-Granados ¹, Rafaela Ortega ³, Maria Carmen Castro ³, Jerusalem Calvo-Gutierrez ³, Pilar Font ¹, Mª Ángeles Aguirre-Zamorano ², Eduardo Collantes-Estevez ¹, Chary Lopez-Pedrera ³ and Nuria Barbarroja ⁶, ¹University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁴Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁵Reina Sofia University Hospital/IMIBIC, Córdoba, Spain, ⁶University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain
Background/Purpose: Patients with rheumatic diseases have an increased risk of cardiovascular disease (CVD). Cardiometabolic disease includes an alteration in metabolic organs and CV system that…
Abstract Number: 2133 • 2019 ACR/ARP Annual Meeting
Acute Myocardial Infarction in Rheumatoid Arthritis, Gout, and Osteoarthritis: A Retrospective Study Using the National Inpatient Sample from 2002-2016
Rouhin Sen¹, Sarah Aurit ², Luay Sarsam ³, Osman Bhatty ⁴, Mukund Kumar ¹ and Joseph Nahas ¹, ¹Creighton University Medical Center, Omaha, NE, ²Creighton University Medical Center, Omaha, ³Arnot Health, Elmira, NY, ⁴Montefiore Medical Center Wakefield Campus, Bronx, NY
Background/Purpose: Inflammation is a risk factor in the development of cardiovascular disease. The proposed etiology centers around accelerated atherosclerosis involving various cytokines in the TNF…
Abstract Number: 2134 • 2019 ACR/ARP Annual Meeting
Extracellular Adenosine Increases IL-6 Production by Aging Tenocytes and May Contribute to the Age-related Pattern of Polymyalgia Rheumatica
Charmi Shah¹, Thomas Garvey ², Claudia Gohr ¹, Elizabeth Mitton-fitzgerald ³ and Ann Rosenthal ³, ¹Medical College of Wisconsin, Milwaukee, WI, ²Mayo Clinic, Rochester, MN, ³Medical College of Wisconsin, Milwaukee
Background/Purpose: Polymyalgia rheumatica (PMR) is a common disease preferentially affecting elderly patients. Characteristically, PMR involves large tendons and muscles around the hips and shoulders. While…
Abstract Number: 2135 • 2019 ACR/ARP Annual Meeting
Therapeutic Strategies and Survival in Patients with Interstitial Pneumonia with Autoimmune Features
Marco Sebastiani¹, Giulia Cassone ², Caterina Vacchi ¹, Lisa De Pasquale ¹, Stefania Cerri ³, Giovanni Della Casa ⁴, Carlo Salvarani ¹ and Andreina Manfredi ¹, ¹Rheumatology Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria Policlinico di Modena, MOdena, Emilia-Romagna, Italy, ²Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Emilia-Romagna, Italy, ³Respiratory Disease Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Emilia-Romagna, Italy, ⁴Radiology Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Emilia-Romagna, Italy
Background/Purpose: Recently the term “interstitial pneumonia with autoimmune features” (IPAF) has been proposed to identify patients with interstitial lung disease and autoimmune characteristics, not fulfilling…
Abstract Number: 2136 • 2019 ACR/ARP Annual Meeting
Cardiovascular Risk Evaluation in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Preliminary Results from the “Cardiovascular Obesity and Rheumatic DISease (CORDIS)” Study Group of the Italian Society of Rheumatology
Fabio Cacciapaglia¹, Gian Luca Erre ², Garifallia Sakellariou ³, Ombretta Viapiana ⁴, Matteo Piga ⁵, Elena Bartoloni ⁶, Andreina Manfredi ⁷, Sergio Colella ¹, Floriana Castagna ², Giacomo Cafaro ⁸, Martina Dessì ⁵, Marco Fornaro ¹, Alessandro Giollo ⁹, Silvia Grignaschi ¹⁰, Caterina Vacchi ¹¹, Francesca Romana Spinelli ¹², Fabiola Atzeni ¹³ and Elisa Gremese ¹⁴, ¹Rheumatology Unit – Department of Emergency and Organs Transplantation, University and AOU Policlinico of Bari, Italy, Bari, Italy, ²Specialità Mediche, Azienda Ospedaliero Universitaria di Sassari, Italy., Sassari, Italy, ³Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ⁴University of Verona, Verona, Italy, ⁵Rheumatology Unit, Department of Medical Sciences, University and AOU Policlinico of Cagliari, Italy., Cagliari, Italy, ⁶Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy, Perugia, Italy, ⁷Rheumatology Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Emilia-Romagna, Italy, ⁸Rheumatology Unit, Department of Medicine, University of Perugia, Italy., Perugia, Italy, ⁹Rheumatology Unit, Department of Medicine, University of Verona, Italy., Verona, Italy, ¹⁰Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy., Pavia, Italy, ¹¹Rheumatology Unit, Department of Medical and Surgical Science, University and AOU Policlinico of Modena, Italy., Modena, ¹²Rheumatology, Department of Internal Medicine and Medical Speciality, Sapienza University of Rome, Italy., Rome, Italy, ¹³Rheumatology Unit, University of Messina, Messina, Italy., Messina, Italy, ¹⁴Fondazione Policlinico Gemelli-Università Cattolica del Sacro Cuore, Rome, Italy
Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients present high cardiovascular (CV) morbidity and mortality. International guidelines suggest estimating CV-risk in these patients,…
Abstract Number: 2137 • 2019 ACR/ARP Annual Meeting
Overall Survival in Patients with PD-1 Inhibitor-related Inflammatory Arthritis and Metastatic Melanoma
Michael Richter¹, Jacob Orme ², Heidi Finnes ³ and Uma Thanarajasingam ⁴, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Hematology and Oncology, Mayo Clinic, Rochester, MN, ³Department of Pharmacy, Mayo Clinic, Rochester, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: The development of de novo inflammatory arthritis (IA) occurs in 2-4% of all patients with cancer treated with programmed cell death protein 1 (PD-1)…
Abstract Number: 2138 • 2019 ACR/ARP Annual Meeting
Rheumatic Immune-related Adverse Effects from Checkpoint Inhibitor Immunotherapy in Patients with Solid Tumors in a Latin American Population
Alain Sánchez-Rodríguez¹, Elina Alexandra Rodriguez-Melendez ², Alonso Turrent-Carriles ³, Paola Bermúdez-Bermejo ³, josé Fabián Martínez-Herrera ² and Raquel Gerson-Cwilich ², ¹Hospital General de Mexico, Mexico City, Distrito Federal, Mexico, ²ABC Medical Center, Oncology Department, Ciudad de Mexico, Distrito Federal, Mexico, ³ABC Medical Center, Rheumatology Department, Ciudad de Mexico, Distrito Federal, Mexico
Background/Purpose: Cancer immunotherapy is a newly-approved approach in the management of advanced malignancies. Immune checkpoint inhibitors (ICIs) are the most commonly used type of cancer…
Abstract Number: 2139 • 2019 ACR/ARP Annual Meeting
Rheumatic Immune-Related Adverse Events Associated with Treatment with Immune Checkpoint Inhibitors: A Multicenter Study of 38 Cases
Sebastian Rodriguez-Garcia¹, David Lobo ², Fabiola Ojeda ³, Raul Castellanos-Moreira ⁴, Ana Laiz ², Roberto Gumucio ⁴, Cesar Diaz-Torné ², Virginia Ruiz-Esquide ⁵, Milena Millan ², Ivan Castellvi ⁶, Patricia Moya Alvarado ⁷, Berta Magallares ², Carolina Perez ³, Hector Corominas ⁸ and Jose Gomez-Puerta ⁹, ¹Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Spain, ²Rheumatology Department. Hospital Sant Pau, Barcelona, Catalonia, Spain, ³Rheumatology Department. Hospital del Mar, Barcelona, Catalonia, Spain, ⁴Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, ⁵Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ⁶Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ⁸Rheumatology Department, Hospital Sant Pau, Barcelona, Catalonia, Spain, ⁹Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain
Background/Purpose: Immune checkpoint inhibitors (ICI) against CTLA-4 or PD- 1/PD-L1 and more recently TIM3, have demonstrated efficacy in improving the survival of patients with diverse…
Abstract Number: 2140 • 2019 ACR/ARP Annual Meeting
Preexisting Autoimmune Disease and Rheumatic Immune-Related Adverse Events Associated with Cancer Immunotherapy: A Case Series from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
Linda Laaouad¹, Janet Roberts ², Daniel Ennis ³, Carrie Ye ⁴, Karam Al Jumaily ⁵, Marie Hudson ⁶, Shahin Jamal ⁷, Janet Pope ⁸, Tatiana Nevskaya ⁹, Alexandra Saltman ¹⁰, Megan Himmel ¹¹, Aurore Fifi-Mah ¹², Annaliese Tisseverasinghe ¹³, Nancy Maltez ¹⁴, Ines Colmegna ¹⁵ and Sabrina Hoa ¹⁶, ¹University of Montreal, Montreal, Canada, ²Dalhousie University, Halifax, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵University of Alberta, Edmonton, Canada, ⁶Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada, ⁷University of British Columbia, Vancouver, BC, Canada, ⁸Western University, London, ON, Canada, ⁹University of Western Ontario, London, ON, Canada, ¹⁰University of Toronto, Mount Sinai Hospital and Princess Margaret Cancer Centre, Toronto, ON, Canada, ¹¹University of Toronto, Toronto, Canada, ¹²University of Calgary, Calgary, AB, Canada, ¹³University of Manitoba, Winnipeg, MB, Canada, ¹⁴University of Ottawa, Ottawa, ON, Canada, ¹⁵McGill University Health Center, Montreal, QC, Canada, ¹⁶University of Montreal, Montreal, QC, Canada
Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by harnessing the immune system to fight cancer, but are associated with significant immune-related adverse events…
Abstract Number: 2141 • 2019 ACR/ARP Annual Meeting
Rituximab Therapy for Interstitial Pneumonia with Autoimmune Features (IPAF): A Case Series of Nineteen Patients
Kristin D'Silva¹, Marcy Bolster ¹, Flavia Castelino ², Amita Sharma ¹, Brent Little ¹, Sydney Montesi ¹ and Hyon K. Choi ¹, ¹Massachusetts General Hospital, Boston, MA, ²Harvard University, Boston, MA
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in patients with connective tissue diseases (CTD). Approximately one-third of patients with…
Abstract Number: 2142 • 2019 ACR/ARP Annual Meeting
Frailty in Systemic Rheumatic Diseases: A Systematic Review
Sarah Lieber¹, Abigail Schmucker ² and Lisa Mandl ³, ¹Hospital for Special Surgery, New York, ²Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, ³Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY
Background/Purpose: Frailty, a state of decreased homeostatic reserve, is well studied in the elderly and is independently associated with increased morbidity and mortality. Many systemic…
Abstract Number: 2143 • 2019 ACR/ARP Annual Meeting
Neuromyelitis Optica Overlaps Frequently with Systemic Rheumatic Diseases in African-Americans: Experience at a Large US Academic Medical Center
Michael Belsky¹, Sunita Dia ², Hassan Amer ², Christopher Collins ¹ and Konstantinos Loupasakis ¹, ¹MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ²MedStar Washington Hospital Center, Department of Internal Medicine, Washington, DC
Background/Purpose: Neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorders (NMOSD) are immune-mediated demyelinating disorders of the central nervous system, primarily characterized by optic neuritis and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].